Beyond Dawlish

Global GLP-1 Receptor Agonist Market Statistics: USD 52.6 Billion Value by 2032

Summary:

• The global GLP-1 receptor agonist market size reached USD 24.6 Billion in 2023.
• The market is expected to reach USD 52.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.82% during 2024-2032.
• North America leads the market, accounting for the largest GLP-1 receptor agonist market share.
• Trulicity represents the majority of the market share in the product segment owing to its reliable effectiveness and ease of once-a-week dosing.  
• Parenteral holds the biggest share in the GLP-1 receptor agonist industry.
• Type 2 diabetes mellitus remain a dominant segment in the market due to the rising prevalence of diabetes among individuals.
• Hospital pharmacies account for the leading distribution channel segment.
• The rising prevalence of type 2 diabetes and obesity is a primary driver of the GLP-1 receptor agonist market.
• Advancements in drug development and the increasing focus on cardiovascular health are reshaping the GLP-1 receptor agonist market.   

Industry Trends and Drivers:

• Increasing Prevalence of Type 2 Diabetes and Obesity:

The increasing prevalence of type 2 diabetes and obesity among the masses worldwide is catalyzing the demand for GLP-1 receptor agonists. These conditions are often interconnected due to lifestyle and dietary habits. There is a rise in the need for effective treatments that manage blood sugar levels and promote weight loss. GLP-1 receptor agonists offer dual benefits as they control glucose and aid in weight reduction, making them highly attractive to both healthcare providers and patients. The growing demand for advanced diabetes care solutions due to the increasing awareness among individuals about the importance of maintaining a healthy body is offering a favorable market outlook. This trend is further supported by public health initiatives aimed at combating obesity and diabetes, encouraging the development and adoption of innovative treatments.    

• Rising Focus on Cardiovascular Health:

GLP-1 receptor agonists are valued not only for their role in glucose control but also for their cardiovascular benefits. These drugs can aid in reducing the risk of major cardiovascular events in patients with type 2 diabetes. The ability to lower cardiovascular risks is making them a preferred option for both endocrinologists and cardiologists. Clinical studies highlight that patients on GLP-1 receptor agonist therapy experience fewer adverse cardiovascular outcomes as compared to those on standard diabetes treatment. This attribute broadens their appeal, as cardiovascular disease is a leading cause of death among individuals with diabetes. The added heart-health advantages improve the clinical relevance of these medications, making them a key component of treatment plans for patients at higher cardiovascular risk.    

• Advancements in Drug Development:

Pharmaceutical companies are investing in research and development (R&D) activities to enhance the efficacy, safety, and delivery methods of these drugs. This includes the introduction of more patient-friendly options, such as oral formulations, which overcome the traditional barrier of injectable-only treatments. Additionally, combination therapies that pair GLP-1 receptor agonists with other antidiabetic agents is gaining traction, offering comprehensive solutions for complex cases. These innovations not only improve therapeutic outcomes but also drive patient adherence, as they reduce the frequency of administration and improve overall convenience. The focus on developing drugs with fewer side effects and better tolerability is supporting the market growth.

Request for a sample copy of this report: https://www.imarcgroup.com/glp-1-receptor-agonist-market/requestsample

GLP-1 Receptor Agonist Market Report Segmentation:

Breakup By Product:

• Victoza
• Ozempic
• Trulicity
• Bydureon
• Saxenda
• Others

Trulicity accounts for the majority of shares owing to its reliable effectiveness and ease of once-a-week dosing.  

Breakup By Route of Administration:

• Parenteral
• Oral

Parenteral dominates the market as it ensures rapid absorption and optimal treatment results.

Breakup By Application:

• Type 2 Diabetes Mellitus
• Obesity
• Others

Type 2 diabetes mellitus represents the majority of shares due to the rising prevalence of diabetes among individuals.  

Breakup By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Diabetes Clinics
• Online Pharmacies

Hospital pharmacies hold the majority of shares on account of their ability to provide specialized care for chronic conditions.   

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position owing to a large market for GLP-1 receptor agonist driven by the presence of well-established healthcare infrastructure.  

Top GLP-1 Receptor Agonist Market Leaders:

The GLP-1 receptor agonist market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Amgen Inc.
• Eli Lilly and Company
• Hanmi Pharm Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Novo Nordisk A/S
• Paige Biomedicine (Suzhou) Co., Ltd.
• Sanofi S.A.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) 91 120 433 0800

United States: 1–631–791–1145